371 related articles for article (PubMed ID: 27177330)
1. mTOR: An attractive therapeutic target for osteosarcoma?
Ding L; Congwei L; Bei Q; Tao Y; Ruiguo W; Heze Y; Bo D; Zhihong L
Oncotarget; 2016 Aug; 7(31):50805-50813. PubMed ID: 27177330
[TBL] [Abstract][Full Text] [Related]
2. mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review).
Hu K; Dai HB; Qiu ZL
Oncol Rep; 2016 Sep; 36(3):1219-25. PubMed ID: 27430283
[TBL] [Abstract][Full Text] [Related]
3. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
[TBL] [Abstract][Full Text] [Related]
4. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway.
Liu B; Xu L; Dai EN; Tian JX; Li JM
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30442873
[TBL] [Abstract][Full Text] [Related]
6. Norcantharidin inhibits proliferation and promotes apoptosis via c-Met/Akt/mTOR pathway in human osteosarcoma cells.
Mei L; Sang W; Cui K; Zhang Y; Chen F; Li X
Cancer Sci; 2019 Feb; 110(2):582-595. PubMed ID: 30520540
[TBL] [Abstract][Full Text] [Related]
7. LHX2 promotes malignancy and inhibits autophagy via mTOR in osteosarcoma and is negatively regulated by miR-129-5p.
Song H; Liu J; Wu X; Zhou Y; Chen X; Chen J; Deng K; Mao C; Huang S; Liu Z
Aging (Albany NY); 2019 Nov; 11(21):9794-9810. PubMed ID: 31724536
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor β induces autophagy of osteosarcoma through the mTOR signaling pathway.
Yang Z; Yu W; Liu B; Yang M; Tao H
J Orthop Surg Res; 2020 Feb; 15(1):50. PubMed ID: 32054506
[TBL] [Abstract][Full Text] [Related]
9. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
Fleuren ED; Versleijen-Jonkers YM; Roeffen MH; Franssen GM; Flucke UE; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
Int J Cancer; 2014 Dec; 135(12):2770-82. PubMed ID: 24771207
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition.
Liao YX; Lv JY; Zhou ZF; Xu TY; Yang D; Gao QM; Fan L; Li GD; Yu HY; Liu KY
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34080667
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells.
Zhou R; Zhang Z; Zhao L; Jia C; Xu S; Mai Q; Lu M; Huang M; Wang L; Wang X; Jin D; Bai X
J Orthop Res; 2011 Jun; 29(6):846-52. PubMed ID: 21246613
[TBL] [Abstract][Full Text] [Related]
12. Physakengose G induces apoptosis via EGFR/mTOR signaling and inhibits autophagic flux in human osteosarcoma cells.
Lin H; Zhang C; Zhang H; Xia YZ; Zhang CY; Luo J; Yang L; Kong LY
Phytomedicine; 2018 Mar; 42():190-198. PubMed ID: 29655686
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma.
Yang J; Cheng D; Zhou S; Zhu B; Hu T; Yang Q
Int J Mol Sci; 2015 Dec; 16(12):28635-46. PubMed ID: 26633383
[TBL] [Abstract][Full Text] [Related]
14. [Inhibitory effect and significance of rapamycin on the mammalian target of rapamycin signaling pathway in osteosarcoma stem cells and osteosarcoma cells].
Liu PY; Zhang WB; Wang J; Shen YH; Wei YY
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):175-80. PubMed ID: 23879996
[TBL] [Abstract][Full Text] [Related]
15. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma.
Jiang H; Zeng Z
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):255-61. PubMed ID: 26514724
[TBL] [Abstract][Full Text] [Related]
16. The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models.
Zhu YR; Zhou XZ; Zhu LQ; Yao C; Fang JF; Zhou F; Deng XW; Zhang YQ
Oncotarget; 2016 Aug; 7(31):49527-49538. PubMed ID: 27385099
[TBL] [Abstract][Full Text] [Related]
17. Chitooligosaccharides inhibit tumor progression and induce autophagy through the activation of the p53/mTOR pathway in osteosarcoma.
Pan Z; Cheng DD; Wei XJ; Li SJ; Guo H; Yang QC
Carbohydr Polym; 2021 Apr; 258():117596. PubMed ID: 33593530
[TBL] [Abstract][Full Text] [Related]
18. The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529.
Hu X; Wang Z; Chen M; Chen X; Liang W
Biochem Biophys Res Commun; 2018 Mar; 497(2):499-505. PubMed ID: 29432734
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis and antitumor effects induced by the combination of an mTOR inhibitor and an autophagy inhibitor in human osteosarcoma MG63 cells.
Horie R; Nakamura O; Yamagami Y; Mori M; Nishimura H; Fukuoka N; Yamamoto T
Int J Oncol; 2016 Jan; 48(1):37-44. PubMed ID: 26530936
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin inhibits tumor growth of human osteosarcomas.
Zhao S; Lu N; Chai Y; Yu X
J BUON; 2015; 20(2):588-94. PubMed ID: 26011354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
